Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest & Investment Income (2022 - 2026)

Centessa Pharmaceuticals has reported Interest & Investment Income over the past 4 years, most recently at $4.5 million for Q4 2025.

  • Quarterly Interest & Investment Income fell 7.29% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, up 46.45% year-over-year, with the annual reading at $20.5 million for FY2025, 46.45% up from the prior year.
  • Interest & Investment Income was $4.5 million for Q4 2025 at Centessa Pharmaceuticals, up from $3.8 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $7.9 million in Q1 2025 and troughed at $25000.0 in Q2 2022.
  • The 4-year median for Interest & Investment Income is $2.9 million (2023), against an average of $2.8 million.
  • Year-over-year, Interest & Investment Income surged 8136.0% in 2023 and then dropped 7.29% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $39000.0 in 2022, then surged by 7420.51% to $2.9 million in 2023, then skyrocketed by 65.19% to $4.8 million in 2024, then dropped by 7.29% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Interest & Investment Income are $4.5 million (Q4 2025), $3.8 million (Q3 2025), and $4.4 million (Q2 2025).